Open Payments

NEWYORK-PRESBYTERIAN/QUEENS

Type
Teaching hospital
Where
FLUSHING, NY
Medicare CCN
330055
Received
$332,135 in 68 records, 2021 ($63,173 general, $268,962 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2021General payment25$63,173
2021Research payment43$268,962

By company

CompanyRecordsAmountYears
Gilead Sciences, Inc.17$100,9162021
Novartis Pharmaceuticals Corporation3$34,0632021
Boston Scientific Corporation6$34,0422021
Abbott Laboratories9$25,1812021
PFIZER INC.3$24,9962021
Aesculap, Inc.10$20,2452021
Novocure Inc.4$19,7812021
BIOTRONIK INC.3$18,9242021
Volta Medical Inc2$17,9932021
Johnson & Johnson Health Care Systems Inc.5$12,2662021
ENDOTRONIX, INC.1$11,5002021
Linvatec Corporation1$4,2722021
SWEDISH ORPHAN BIOVITRUM AB1$3,6702021
Mallinckrodt Hospital Products Inc.1$2,4962021
Welch Allyn1$9852021
Stryker Corporation1$7992021

By nature of payment

NatureRecordsAmount
Research payment43$268,962
Debt forgiveness23$57,701
Long term medical supply or device loan1$4,272
Consulting Fee1$1,200

Records

DateCompanyAmountNatureFormProductStudyYear
2021-12-31Linvatec Corporation$4,272Long term medical supply or device loanIn-kind items and servicesAIRSEAL Device, GENERAL SURGERY2021
2021-12-31Stryker Corporation$799Debt forgivenessCash or cash equivalent2021
2021-12-22Gilead Sciences, Inc.$1,472Research paymentCash or cash equivalentA Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt2021
2021-12-16Volta Medical Inc$4,893Research paymentCash or cash equivalentVX1 Device, Cardiac ElectrophysiologyTailoredAF2021
2021-11-23Abbott Laboratories$12,735Research paymentCash or cash equivalentAbsorb GT1 Device, VascularA Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects2021
2021-11-23Welch Allyn$985Debt forgivenessCash or cash equivalentNone Device, Not Applicable2021
2021-11-19Mallinckrodt Hospital Products Inc.$2,496Debt forgivenessCash or cash equivalentOFIRMEV Drug, ACUTE CARE2021
2021-11-09PFIZER INC.$1,500Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A 2021
2021-11-04ENDOTRONIX, INC.$11,500Research paymentCash or cash equivalentCORDELLA PULOMONARY ARTERY PRESSURE SENSOR Device, HEART FAILUREPROACTIVE-HF2021
2021-10-28Boston Scientific Corporation$12,735Research paymentIn-kind items and servicesVARIOUS RELEASED ICD FAMILIES Device, Clinical Trial ProductLONGEVITY STUDY2021
2021-10-18Gilead Sciences, Inc.$10,065Research paymentCash or cash equivalentVeklury Drug, COVID-19Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre2021
2021-10-18Johnson & Johnson Health Care Systems Inc.$5,285Debt forgivenessIn-kind items and services2021
2021-10-18Johnson & Johnson Health Care Systems Inc.$1,434Debt forgivenessIn-kind items and services2021
2021-10-18Johnson & Johnson Health Care Systems Inc.$271Debt forgivenessIn-kind items and services2021
2021-10-07Gilead Sciences, Inc.$15,925Research paymentCash or cash equivalentA Phase 2 Randomized, Open-Label, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen o2021
2021-09-30Novocure Inc.$8,675Research paymentCash or cash equivalentEF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi2021
2021-09-24Abbott Laboratories$766Debt forgivenessCash or cash equivalent2021
2021-09-23Novocure Inc.$1,012Research paymentCash or cash equivalentEF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi2021
2021-09-22Gilead Sciences, Inc.$2,066Research paymentCash or cash equivalentA Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt2021
2021-09-16Novartis Pharmaceuticals Corporation$1,000Research paymentCash or cash equivalentENTRESTO Drug, CARDIOVASCULARA Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and S2021
2021-09-14Johnson & Johnson Health Care Systems Inc.$4,330Debt forgivenessIn-kind items and services2021
2021-09-13Abbott Laboratories$666Debt forgivenessCash or cash equivalent2021
2021-09-09Novocure Inc.$7,056Research paymentCash or cash equivalentEF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi2021
2021-09-07Boston Scientific Corporation$916Research paymentIn-kind items and servicesGeneral Tachy Device, TachyLONGEVITY STUDY2021
2021-09-07Boston Scientific Corporation$280Research paymentIn-kind items and servicesVARIOUS RELEASED ICD FAMILIES Device, Clinical Trial ProductLONGEVITY STUDY2021
2021-09-01Volta Medical Inc$13,100Research paymentCash or cash equivalentVX1 Device, Cardiac ElectrophysiologyTailoredAF2021
2021-08-10PFIZER INC.$10,000Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A 2021
2021-08-04Gilead Sciences, Inc.$15,125Research paymentCash or cash equivalentVeklury Drug, COVID-19Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre2021
2021-08-03Aesculap, Inc.$5,343Debt forgivenessCash or cash equivalent2021
2021-08-03Aesculap, Inc.$4,000Debt forgivenessCash or cash equivalent2021
2021-08-03Aesculap, Inc.$3,072Debt forgivenessCash or cash equivalent2021
2021-08-03Aesculap, Inc.$2,136Debt forgivenessCash or cash equivalent2021
2021-08-03Aesculap, Inc.$1,984Debt forgivenessCash or cash equivalent2021
2021-08-03Aesculap, Inc.$1,547Debt forgivenessCash or cash equivalent2021
2021-08-03Aesculap, Inc.$810Debt forgivenessCash or cash equivalent2021
2021-08-03Aesculap, Inc.$772Debt forgivenessCash or cash equivalent2021
2021-08-03Aesculap, Inc.$344Debt forgivenessCash or cash equivalent2021
2021-08-03Aesculap, Inc.$233Debt forgivenessCash or cash equivalent2021
2021-06-23Gilead Sciences, Inc.$1,472Research paymentCash or cash equivalentA Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt2021
2021-06-22BIOTRONIK INC.$1,200Consulting FeeCash or cash equivalentPlexa Device, Cardiology/Vascular Diseases2021
2021-06-09Gilead Sciences, Inc.$16,000Research paymentCash or cash equivalentVeklury Drug, COVID-19Incidence of Acute Kidney Disease in COVID-19 Patients Receiving Remdesivir2021
2021-06-02Novartis Pharmaceuticals Corporation$22,522Research paymentCash or cash equivalentENTRESTO Drug, CARDIOVASCULARPROSPECTIVE COMPARISON OF ARNI WITH ARB GIVEN FOLLOWING STABILIZATION IN DECOMPENSATED HFPEF (PARAGLIDE-HFPEF)2021
2021-06-02Boston Scientific Corporation$10,000Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTUsing Cardiovascular Implantable Electronic Device Data to Identify Early Indicators of COVID 19 Infection and to Predic2021
2021-05-31BIOTRONIK INC.$1,586Debt forgivenessCash or cash equivalent2021
2021-05-19Gilead Sciences, Inc.$2,066Research paymentCash or cash equivalentA Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt2021
2021-05-19Gilead Sciences, Inc.$1,032Research paymentCash or cash equivalentVeklury Drug, COVID-19Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre2021
2021-04-30BIOTRONIK INC.$16,138Debt forgivenessCash or cash equivalent2021
2021-04-27Abbott Laboratories$6,559Research paymentCash or cash equivalentXience V coronary stent system Device, VascularAbbott Vascular / XIENCE2021
2021-04-27Abbott Laboratories$1,000Research paymentCash or cash equivalentXience V coronary stent system Device, VascularAbbott Vascular / XIENCE2021
2021-04-27Abbott Laboratories$600Research paymentCash or cash equivalentXience V coronary stent system Device, VascularAbbott Vascular / XIENCE2021
2021-04-27Boston Scientific Corporation$110Research paymentIn-kind items and servicesEnergen Device, TachyLONGEVITY STUDY2021
2021-04-26Gilead Sciences, Inc.$19,050Research paymentCash or cash equivalentVeklury Drug, COVID-19Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre2021
2021-04-26Gilead Sciences, Inc.$1,269Research paymentCash or cash equivalentA Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt2021
2021-04-14Abbott Laboratories$1,750Debt forgivenessCash or cash equivalent2021
2021-03-23Boston Scientific Corporation$10,000Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTUsing Cardiovascular Implantable Electronic Device Data to Identify Early Indicators of COVID 19 Infection and to Predic2021
2021-03-17Gilead Sciences, Inc.$2,066Research paymentCash or cash equivalentA Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt2021
2021-03-17Gilead Sciences, Inc.$1,134Research paymentCash or cash equivalentVeklury Drug, COVID-19Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre2021
2021-03-14PFIZER INC.$13,496Research paymentIn-kind items and servicesCOMIRNATY Biological, VACCINESA PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A 2021
2021-02-26Novocure Inc.$3,037Research paymentCash or cash equivalentEF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi2021
2021-02-17Gilead Sciences, Inc.$1,801Research paymentCash or cash equivalentVeklury Drug, COVID-19Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre2021
2021-02-17Gilead Sciences, Inc.$864Research paymentCash or cash equivalentA Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt2021
2021-02-11Abbott Laboratories$780Research paymentCash or cash equivalentAbsorb GT1 Device, VascularA Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects2021
2021-01-29Johnson & Johnson Health Care Systems Inc.$944Debt forgivenessIn-kind items and services2021
2021-01-27Novartis Pharmaceuticals Corporation$10,541Research paymentCash or cash equivalentENTRESTO Drug, CARDIOVASCULARPROSPECTIVE COMPARISON OF ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR ARNI VERSUS ACE INHIBITOR TRIAL TO DETERMINE IMPACT 2021
2021-01-26Abbott Laboratories$325Research paymentCash or cash equivalentXience V coronary stent system Device, VascularAbbott Vascular / XIENCE2021
2021-01-25SWEDISH ORPHAN BIOVITRUM AB$3,670Research paymentCash or cash equivalentKINERET Drug, IMMUNOLOGYSOBI.IMMUNO-1012021
2021-01-20Gilead Sciences, Inc.$8,240Research paymentCash or cash equivalentVeklury Drug, COVID-19Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre2021
2021-01-20Gilead Sciences, Inc.$1,269Research paymentCash or cash equivalentA Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt2021

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

In New York; placed by its state only.

MeasureState
New York
Population B0100319,852,366
Population, 2020 census P120,201,249
Median age B0100239.8
Under 18 B0100120.5%
65 and over B0100117.9%
Households B110017,722,646
Foreign born B0500222.8%
Median household income B19013$85,974
Median family income B19113$106,873
Per capita income B19301$50,712
Poverty rate B1700114.0%
Unemployment rate B230256.4%
Civilian labor force B2302510,171,766
Mean commute (minutes) B0801332.6
Bachelor's degree or higher B1500340.2%
Housing units B250018,585,241
Owner-occupied B2500354.3%
Renters B2500345.7%
Median home value B25077$423,800
Median gross rent B25064$1,621
White, not Hispanic B0300252.8%
Black B0300213.4%
Hispanic or Latino B0300219.8%
Asian B030029.0%
American Indian and Alaska Native B030020.2%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New York.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.